.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Merck
US Department of Justice
Healthtrust
Dow
AstraZeneca
Deloitte
Chubb
US Army
Cerilliant

Generated: June 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,871,779

« Back to Dashboard

Claims for Patent: 8,871,779

Title:Process for preparing morphinan-6-one products with low levels of .alpha.,.beta.-unsaturated ketone compounds
Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) ##STR00001##
Inventor(s): Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Application Number:11/915,606
Patent Claims: 1. A hydrochloride salt of oxymorphone comprising less than 0.001% of 14-hydroxymorphinone.

2. The hydrochloride salt of claim 1 comprising less than 0.0005% of 14-hydroxymorphinone.

3. A pharmaceutical acceptable form comprising the oxymorphone hydrochloride according to claim 1.

4. A hydrochloride salt of a morphinan-6-one compound corresponding to Formula (2): ##STR00026## comprising less than 0.001% measured by HPLC of an .alpha.,.beta.-unsaturated ketone compound corresponding to Formula (3): ##STR00027## wherein the morphinan-6-one compound is oxymorphone and wherein X is --N(R.sub.17)--; R.sub.1 and R.sub.2 are hydrogen; R.sub.3 is hydroxy; R.sub.10 is hydrogen; R.sub.14 is hydroxy; and R.sub.17 is methyl.

5. The hydrochloride salt of claim 4 comprising less than 0.0005% of 14-hydroxymorphinone.

6. A pharmaceutical formulation comprising the oxymorphone hydrochloride according to claim 4.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Covington
Farmers Insurance
UBS
Novartis
Harvard Business School
QuintilesIMS
Johnson and Johnson
Daiichi Sankyo
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot